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Abstract: A click chemistry-based approach was implemented to 
prepare peptidomimetics designed in silico and made from aromatic 
azides and a propargylated GIGI-mimicking platform derived from 
the altered Melan-A/MART-126(27L)-35 antigenic peptide ELAGIGILTV. 
The Cu(I)-catalyzed Huisgen cycloaddition was carried out on solid 
support to generate rapidly a first series of peptidomimetics, which 
were evaluated for their capacity to dock at the interface between 
the major histocompatibility complex class-I (MHC-I) human 
leucocyte antigen (HLA)-A2 and T-cell receptors (TCRs). Despite 
being a weak HLA-A2 ligand, one of those 11 first synthetic 
compounds bearing a p-nitrobenzyl-triazole side-chain was 
recognized by the receptor proteins of Melan-A/MART-1-specific T-
cells. After modifications of the N- and C-termini of this agonist, 
which was intended to enhance HLA-A2 binding, one of the resulting 
7 additional compounds triggered significant T-cell responses. Thus, 
these results highlight the capacity of naturally circulating human 
TCRs that are specific for the native Melan-A/MART-126-35 peptide to 
cross-react with peptidomimetics bearing organic motifs structurally 
different from the native central amino acids. 
Introduction 
Melanoma is a malignant tumour arising from melanocytes and 
causes the majority (75%) of deaths in patients suffering of skin 
cancer. Over the past decade, the percentage of persons who 
have developed melanoma has considerably increased. 
According to the world health organization (WHO), this cancer 
disease currently affects 132,000 individuals, and globally each 
year incidence is increasing (AICR). The identification of 
melanoma-associated antigens recognized by CD8+ T-cells 
(MART) from melanoma patients has raised new prospects in 
the development of immunotherapeutic agents to treat this 
cancer. Melan-A/MART-1 (hereafter referred to as Melan-A) is a 
tissue-specific differentiation antigen expressed in melanocytes 
and melanoma.[1] In the late 1990s, Romero and co-workers 
identified the peptide segment Melan-A(26-35) (sequence: 
EAAGIGILTV, hereafter referred to as EAA) as being an 
immunodominant epitope frequently recognized by CD8+ tumor-
infiltrating T- lymphocytes (TIL).[2,3] Indeed, a recent analysis of 
the dominant tumor-reactive clonotypes in the blood of an HLA-
A2+ stage IV melanoma patient successfully treated with TIL 
therapy found that three out of the five most expanded 
clonotypes, accounting for >44% of the total response to tumor 
in blood following complete remission, were specific for the EAA 
epitope.[4] Moreover, actual therapeutic strategies aiming at 
blocking the down-regulation of CD8+ T-cells boost Melan-A 
specific T-cell immunity, which is promising for the development 
of melanoma immunotherapy.[5] 
The EAA antigenic peptide stems from the degradation of 
Melan-A antigen. This agonist is then loaded onto the major 
histocompatibility class-I (MHC-I) HLA-A2 molecule in the 
endoplasmic reticulum, and finally transported to the cell surface 
for inspection by T-cell receptors (TCRs).[6] MHC-I proteins bind 
peptides adopting an extended or bulged conformation through 
the combination of conserved hydrogen bonds with the peptide 
main-chain and allele-specific pockets that accommodate some 
of the side-chains of peptide. For the HLA-A2 molecule, the key 
binding sites are two anchoring pockets that accommodate 
hydrophobic amino acid side-chains at P2 and C-terminal 
positions.[7] Because the EAA epitope presents a weak binding 
affinity to HLA-A2 due to the lack of an optimal residue at P2, 




residue at P2 by a leucine (sequence: ELAGIGILTV, hereafter 
referred to as ELA). The ELA peptide was found to be a high-
affinity ligand capable of triggering CD8+ T cell responses 
stronger than those triggered by the EAA peptide.[8] However, 
further studies have shown that ELA and EAA prime different 
TCRs in vivo when used in clinical trials,[9] even though X-ray 
crystal structures of both EAA/HLA-A2 and ELA/HLA-A2 
complexes revealed no major differences in the global 
architecture of the peptides with conservation of the bulged 
conformation.[10] 
Other structural modifications of ELA were also performed in 
the aim of enhancing its stability in biological fluids, while 
maintaining high HLA-A2 binding affinity and efficacious 
immunogenicity.[11] These modifications consisted of replacing 
the N- and/or C-terminal regions, which are known to be more 
exposed to the action of proteases, by chemically altered or non-
natural amino acids.[12] A few years ago, we opted for a less 
classical peptidomimetic approach for the construction of ELA 
analogues. Instead of iteratively modifying the terminal ELA 
parts bound to the HLA-A2 protein, we focused our efforts on 
alterations of the central TCR-contacting GIGI portion by relying 
on non-peptidic units, which were either tethered to this 
tetrapeptide or used to replace it.[13] These studies demonstrated 
the possibility of TCR recognition of haptens with chemical 
features drastically different from those of standard amino acids, 
while maintaining significant Melan-A specific T-cell recognition. 
In particular, a structure-guided rational design led us to prepare 
an ELA-mimetic presenting a central unit equipped with an 
indole acetic acid side-chain (see 1 in Scheme 1a), which 
triggered potent Melan-A specific T-cell responses.[13b] Our X-ray 
crystal structure of this ELA-mimetic 1 bound to the HLA-A2 
protein[14] revealed that the central indole moiety of 1 is oriented 
toward the a2 helix of the HLA-A2 binding groove instead of 
bulging out toward the TCR loops as our in silico simulation of 
the A6-TCR/1/HLA-A2 ternary complex predicted.[13b,14] 
Nevertheless, since 1 has the ability to stimulate Melan-A 
specific T-cells, it likely undergoes some conformational 
changes when contacting TCRs, as previously observed for 
several HLA-A2-binding antigenic peptides.[15] 
 
Scheme 1. a) ELA-mimetic 1 triggers potent Melan-A specific CD8+ T-cell 
responses.[13b] b) Novel ELA-mimetics equipped with various clicked haptens 
(1R-1,2,3-triazole). 
The promising results thus obtained with the ELA-mimetic 1 
encouraged us to pursue this peptidomimetic approach. We 
used a click chemistry-based methodology to embed a selection 
of organic haptens in the GIGI-mimicking platform of our ELA-
mimetic core structure (Scheme 1b). The copper(I)-catalyzed 
azide-alkyne Huisgen 1,3-dipolar cycloaddition (CuAAC) 
reaction was chosen for this task, since it offers a convenient 
and selective access to 1,4-disubstituted 1,2,3-triazoles and has 
found many useful applications in bioconjugate chemistry and 
drug discovery research.[16,17] Our selection of structures was 
again guided by a simulation of their docking at the TCR/MHC-I 
interface. The best performing ELA-mimetics were further 
modified to increase their HLA-A2 binding affinity and their 
resistance to proteases. Herein, we describe the identification of 
a highly heteroclitic HLA-A2 ligand for Melan-A specific CD8+ T-
cells. 
Results and Discussion 
In silico rational design. CD8+ T-cell-mediated immune 
responses are initiated by molecular contacts between the TCR 
and peptide/MHC-I complex (pMHC-I). It is now well established 
that even though antigen specificity is the hallmark of the CD8+ T 
cell activation, a given TCR can exhibit a degree of plasticity, 
hence allowing it to interact with different pMHC-I ligands.[18] This 
cross-reactivity is, in part, the result of conformational 
adjustments at the TCR/pMHC-I interface that enable the 
formation of ternary complexes. Numerous structural and 
biophysical studies have emphasized the structural adaptability 
of TCRs and have demonstrated that significant changes 
between their unbound and bound states can occur upon 
binding to pMHC-I.[19]  In this context, Baker and co-workers 
have explored the A6-TCR cross-reactivity by replacing the 
tyrosine at P5 in the viral Tax peptide sequence with a lysine, 
whose side-chain amino group was coupled to indole-3-butyric 
acid (i.e., Tax5K-IBA, depicted in orange in Figure 1).[20]  The X-
ray crystal structure of the A6-TCR/Tax5K-IBA/HLA-A2 complex 
revealed that binding proceeded through changes in the 
conformation of the complementarity determining region 3 
(CDR3) loops of the TCR (see Figure 1), although the overall 
A6-TCR binding orientation was conserved.[20] 
 
Figure 1. Pymol superimposition of the clicked ELA-mimetic variant 11 (green) 
in the Tax5K-IBA (orange) binding interface of the A6-TCR/Tax5K-IBA/HLA-A2 
ternary complex (PDB 2GJ6). The orientation of the anchoring residue side-
chains, as well as the overall conformations, are maintained. The clicked 
hapten side-chain of 11 bulges out from the HLA-A2 binding groove and is well 




































frame is depicted the phthalimide moiety with H-bonding interactions predicted 
by LigandFit. 
These observations on the structural adaptability of TCRs lent 
support to our intent of equipping ELA-mimetics with sterically 
demanding clicked organic haptens. We explored the impact of 
elongating the central side-chain with a triazole-based system 
on the overall conformation of our ELA-mimetics within the HLA-
A2 binding groove, and which orientation these central side-
chains could adopt within the TCR/HLA-A2 interface. Since no 
ternary complex structure involving the ELA peptide or 
analogues thereof was reported at the time we initiated this 
project, we surmised that the overall conformation of ELA would 
be similar to those of any antigenic peptide presented by the 
HLA-A2 protein with a quasi-complete superimposition of the 
anchoring residue side-chains.[13b] We thus decided to rely on 
the A6/Tax5K-IBA/HLA-A2 structural data (PDB 2GJ6) to guide 
our docking studies. Nonetheless, Sewell and co-workers then 
reported the first X-ray crystal structure of ELA/HLA-A2 in 
complex with the MEL5-TCR (PDB 3HG1).[21] Remarkably, the 
conformation of the ELA peptide engaged with the MEL5-TCR is 
very similar to its conformation when only bound to the HLA-A2 
protein with a root mean squared deviation of 0.369 Å.[10,21] 
Furthermore, this study emphasized that the TRAV12-2 gene, 
which encodes the CDR1a and CDR2a loops of the MEL5 TCR, 
is also expressed by the A6 TCR. Hence, the CDR1a and 
CDR2a loops of the A6-TCR utilize a binding mode that is 
identical to that observed for MEL5/ELA/HLA-A2 complex. In 
particular, the CDR1a loop residue Gln31 makes conserved 
contacts with the peptide positions P1 and P4 (Glu1 and Gly4 for 
ELA; Leu1 and Gly4 for Tax5K-IBA). These structural and 
binding mode analogies between the MEL5 and A6 TCRs 
validated our choice of relying on the A6/Tax5K-IBA/HLA-A2 
structure as a model to guide the docking of our ELA-mimetics. 
The shape-based docking engine LigandFit, from the 
Accelrys Cerius2 software package, was utilized to realize a 
virtual screening of the envisaged peptidomimetics. Hence, our 
initial GIGI-mimicking platform was retained (Scheme 1) and the 
incorporation of organic azides clicked on an alkyne installed 
onto its N-(2-aminoethyl)glycine unit was viewed as a 
convenient synthesis approach (Schemes 1 and 2), notably 
given the wider commercial availability of organic azides as 
compared to that of alkynes. Moreover, the replacement of 
glutamic acid at P1 by a b-alanine was maintained as this 
substitution improves the stability of the resulting analogues in 
biological fluids.[11a] Besides applying the same checkpoints as 
those used for designing the ELA-mimetic 1,[13b] here we also 
checked for the presence of potential contacts between the 
CDR1a residue Gln31 and the N-terminal part of our in silico 
engineered clicked ELA-mimetic variants, as it has been shown 
to play a key role in the recognition of the ELA peptide.[21] 
Clicked ELA-mimetics Synthesis. Diverse organic azides were 
prepared in solution and clicked on the alkyne of the GIGI-
mimicking platform, which was covalently bound to a solid 
support (Scheme 2). Several examples of CuAAC reactions on 
solid phase have been reported either to introduce 1,2,3-triazole 
moiety in peptoid backbones,[22] to realize cyclodimerization of 
peptides,[23] as well as to display various triazole-linked organic 
motifs on oligopeptoids.[24] Our strategy was based on a post-
synthesis CuAAC reaction of the full peptoid alkyne resin 5 with 
various azides R–N3 (Scheme 2). Inclusion of the alkyne was 
thus accomplished during the course of the solid phase 
synthesis (SPS) via a nucleophilic substitution reaction between 
the a-bromoacetamide resin 3 and propargylamine. A reductive 
amination in the presence of N-Fmoc-glycinal was then carried 
out to complete the synthesis of the GIGI-mimicking moiety and 
was followed by the introduction of the remaining amino acids to 
furnish the propargylated resin 5. The CuAAC reactions were 
next performed using pre-synthesized azides R–N3 (see the 
Supporting Information for details), copper(I) iodide as catalyst 
and N,N-diisopropylethylamine (DIPEA) in a dimethylformamide 
(DMF)/tetrahydrofuran (THF) solvent mixture. No ascorbic acid 
was used to maintain the copper in its +1 oxidation state.[22a,25] 
The organic azides R–N3 selected through our preliminary virtual 
screening were all benzylic-type azides (see Scheme 2). After 
classical cleavage from the resin using trifluoroacetic acid (TFA), 
the resulting clicked ELA-mimetics 7-17 were purified by semi-
preparative reverse-phase HPLC (see the Supporting 
Information). 
  
Scheme 2. Synthesis of clicked ELA-mimetics 7-17 via a CuAAc reaction on 
solid support: i) piperidine/DMF (1:4); ii) bromoacetic acid (0.4 M), N,N’-
diisopropylcarbodiimide (DIC, 2 M), DMF, 5 min, rt; iii) propargylamine, DMSO; 
iv) Fmoc-Gly-H, NaBH3CN, 1% AcOH/DMF, 20 h, rt; v) end of SPPS; vi) R–N3, 
DIPEA, CuI, THF/DMF (1:1) (TBDMS = tert-butyldimethylsilyl); vii) release 
from resin and final deprotection using TFA/TIS/H2O (95:2.5:2.5) (see the 
Experimental Section and the Supporting Information for details).  
Immunological Evaluation. Peptide antigenicity is influenced 
by the affinity of the peptide to the MHC-I protein, and in some 
cases, enhancing peptide binding has been shown to enhance 
T-cell recognition and immunogenicity.[26] Our clicked ELA-
mimetics 7-17 were thus first evaluated by a flow cytometry-
based MHC-I stabilization assay using the HLA-A2+ human 
mutant T2 cell line. The ELA peptide and its clicked analogues 
were used at a concentration of 10 µM and HLA-A2 binding was 
determined by the ability of those compounds to stabilize the 















































































T2 cells. Binding was quantified by mean fluorescence 
intensities (MFI), the values of which were then normalized 
relative to the value measured for the ELA peptide (Figure 2). All 
of our synthetically modified ELA-mimetics bound with weaker 
affinities to the HLA-A2 molecule as compared to that of the ELA 
peptide. Although the primary anchoring residues at P2 and P10 
of HLA-A2 are conserved, the triazole-based central side-chains 
of 7-17 are both longer and bulkier than that of our original ELA-
mimetic 1 (see Scheme 1). These results could be in compliance 
with the observations made on the crystal structure of the 
1/HLA-A2 binary complex,[14] showing the central indolic side-
chain of 1 oriented toward the a2 helix of the HLA-A2 protein. 
Thus, increasing both the length and steric demand of the 
central side-chain of our peptidomimetic variants could indeed 
affect their HLA-A2 binding affinity. Even if such a rationale is 
admittedly simplistic, it finds support in the fact that the binding 
affinity decreases when the size and hydrophobicity of the 
hapten units increases, the ELA-mimetics 14 to 17 exhibited the 
lowest HLA-A2 binding affinity. Therefore, we decided to pursue 
our investigations without these peptidomimetics, whose HLA-
A2 binding affinities were more than 5-fold weaker than that of 
ELA (i.e., 14-17 with MFI below 20 in Figure 2). 
  
Figure 2. HLA-A2 binding affinities of the 18 clicked ELA-mimetics as 
measured by flow cytometry mean fluorescence intensity (MFI). Data are 
presented as percentage of positive control (ELA). Negative control 
autofluorescence has been subtracted from all values. 10 μM of compound 
was used for binding analysis. ELA-mimetics with binding affinities below the 
threshold value indicated by the dashed red line (MFI = 20) were excluded 
from further analyses (i.e., 14-17).  
The selected ELA-mimetics 7-13 were then all evaluated for 
their capacity to stimulate Melan-A-specific T-cell responses in 
vitro. Here, an intracellular cytokine stain (ICS) was performed 
and T-cell activation was measured by flow cytometry. Briefly, a 
T-cell line was generated by stimulating HLA-A2+ peripheral 
blood mononuclear cells (PBMC) with the native EAA peptide. 
The resulting Melan-A-specific T-cell line was subsequently 
stimulated with our ELA-mimetics or the native EAA peptide, and 
T-cells examined by flow cytometry for expression of the 
lysosomal-associated membrane protein (LAMP) CD107a[27] and 
for intracellular expression of the cytokine interferon-γ (IFNγ) 
(Figure 3, and see the Experimental Section). Two of these ELA-
mimetic variants bearing central benzyl-type haptens (i.e., 9 and 
11) induced significant Melan-A specific T-cell responses, but 
not to the extent of the native EAA peptide ligand. Interestingly, 
the p-nitrobenzyl-bearing compound 11, which was the weakest 
HLA-A2 ligand of this selection of ELA-mimetics (see Figure 2), 
was capable of triggering the production of CD107a and IFNg at 
notable levels  (see Figure 3).  The ELA-mimetic 9, which is 
equipped with a p-fluorobenzyl-type hapten and characterized 
by a much higher HLA-A2 binding affinity, was found to be a 
weaker agonist. In contrast to 11, the other two nitrobenzylated 
peptidomimetics 12 and 13 were not markedly recognized by T-
cells, despite their higher HLA-A2 binding affinities (see Figure 
2). These results further demonstrate that the level of binding 
affinity of a ligand to MHC-I proteins does not presume of its 
immunogenic potency. Nevertheless, it would seem that the 1-
(4-nitrobenzyl)-1,2,3-triazole side-chain of 11 confers some 
minimum threshold for engaging TCRs, even though it is not a 
good ligand for the HLA-A2 molecule. At this stage of our 
investigations, we then wondered whether further modifying the 
structure of 11 by altering its N- and C-terminal portions, which 
are essential for the loading of any antigenic peptide onto MHC-I 
proteins and also highly sensitive to the action of exoproteases, 
would improve immunogenicity.[11a] 
 
Figure 3. CD107a and IFNγ expressions as measured by intracellular cellular 
staining (ICS) and quantified by flow cytometry. Data are presented by mean 
fluorescence intensity (MFI) after 10 μM stimulation with a select set of our 
ELA-mimetics. Negative control autofluorescence has been subtracted from all 
values. Positive control (native EAA peptide) is shown.  
Modification of N- and C-terminal portions. Structural and 
biophysical studies have highlighted the crucial role of 
conserved amino acids at P2 and C-terminal positions in binding 
to the cleft of HLA-A2 proteins.[7] Thus, to improve the HLA-A2 
binding capacity of our clicked ELA-mimetic 11, as well as its 
resistance against proteolysis, we first envisioned to install a 
non-natural amino acid that could penetrate more deeply into the 
hydrophobic pocket occupied by the leucine at P2. To this aim, 
we selected the non-natural L-cyclohexylalanine (Cha, Figure 4), 
which was previously used as a substituent of phenylalanine to 
improve hydrophobic interactions.[28] Moreover, our crystal 
structure of the ELA-mimetic 1 bound to the HLA-A2 protein[14] 
revealed an unpredicted conformation of the N-terminal b-
alanine disrupting key hydrogen bonds with Lys66 and Glu63 of 
the HLA-A2 a1 helix. In order to recover these interactions, the 
b-alanine could potentially be replaced by a phthalimide moiety. 
Molecular modeling indicated that this rigid, flat dioxoisoindolic 
system can promote the establishment of intermolecular 




















RFI ratio    MFI
MFI
IFN-γCD107a




contacts with the side-chains of α1 helix Lys66 and Glu63 
residues (Figure 1).[29] The restoration of hydrogen bonds with 
these residues should stabilize binary complexes between the 
HLA-A2 molecule and our ELA-mimetics, and their N-terminal 
phthalimide unit should further protect them against the action of 
exoproteases. 
Finally, crystal structures involving the ELA peptide or our 
ELA-mimetic 1 have shown that the carbonyl oxygen of the 
leucine at P8 is not engaged with any HLA-A2 residue.[10,14,21]  
We thus introduced a reduced peptide bond (Y(CH2-NH)) 
between this leucine residue and the adjacent threonine at P9. 
Such a peptide bond isostere, which provides an additional 
degree of conformational flexibility, was viewed as a means to 
favor adequate positioning of the C-terminal extremity of our 
peptidomimetics. These three types of modifications were 
implemented in an iterative manner in order to facilitate the 
determination of their specific contribution to the improvement of 
the HLA-A2 binding affinity (Figure 4 and Scheme 2). Seven 
additional clicked ELA-mimetics 18-24, all bearing the same 
central 1-(4-nitrobenzyl)-1,2,3-triazole side-chain, were thus 
prepared by conventional solid support synthesis (see the 
Experimental Section and the Supporting Information). 
  
Figure 4. Sequences of the ELA-mimetics 18-24, analogues of the ELA-
mimetic 11 designed for improving HLA-A2 binding affinity. 
Gratifyingly, most of the new clicked ELA-mimetics 18-24 
exhibited a two- to three-fold improvement in HLA-A2 binding 
affinity relative to that of 11, with MFI values reaching over two-
thirds of that of the ELA peptide, except for 20, being the 
weakest HLA-A2 binder of this series (Figure 2). In particular, 
the introduction of the non-natural amino acid Cha in the 
structure of 18 fulfilled our expectations based on the hypothesis 
of better occupying the hydrophobic P2 anchoring pocket. The 
introduction of a phthalimide moiety in place of the N-terminal b-
Ala appeared to be also a suitable replacement as the 
corresponding mimetic 19 bound well to the HLA-A2 molecule. 
Of course, without any confirmation by X-ray structural analysis, 
it is, as yet, unclear whether this increase in binding affinity is 
the consequence of H-bonding interactions between the 
carbonyls of the phthalimide unit and the side-chains of the HLA-
A2 Lys66 and Glu63. Nonetheless, a previous study reported 
that replacing the N-terminal glutamate by its constrained 
pyroglutamate lactamic analogue was deleterious for binding to 
HLA-A2,[11a] whereas herein the phthalimide moiety appeared to 
be a valuable N-terminal building block. The reduced peptide 
bond at P8-P9 also seems to be well tolerated, although the 
mimetic 20 exhibited a slightly weaker HLA-A2 binding affinity 
relative to those of 18 and 19 (see Figure 2). Nevertheless, 
when this reduced peptide bond was introduced in combination 
with the Cha or phthalamide residues or even both, the resulting 
mimetics 21, 22 and 24 exhibited very good binding affinities, 
given the number of structural modifications they feature relative 
to the structure of the native EAA antigenic peptide. All together, 
these results corroborate our predictions about how to restore 
good HLA-A2 binding affinity. Moreover, a higher protease 
resistance of these ELA-mimetics should be observed, since 
these last modifications were implemented at scissile peptide 
bonds.[11a]  
Evaluating the immunogenicity of this second series of 
clicked ELA-mimetic variants 18-24 showed that the ELA-
mimetic 20 was the most potent inducer of CD107a upregulation 
and IFN-g secretion. Only two other peptidomimetics of the 
series, 18 and 23, managed to induce Melan-A-specific T-cell 
responses, but to a much lesser extent (Figure 3). Surprisingly, 
once again, the weakest HLA-A2 binder 20 of the series 
exhibited the strongest immunogenicity. One possible 
explanation could be that the lowest binding affinity is the 
consequence of a higher flexibility of the peptidoid backbone in 
the HLA-A2 binding groove, which would in turn enable more 
extensive conformational adjustments upon TCR engagement. 
The TCR could perhaps even pull the weakly binding 
peptidomimetic away from the HLA-A2 binding groove for 
establishing better contacts with both the peptidomimetic and 
the HLA-A2 surface.[10a,15] The more flexible ELA-mimetic 20 
could thus be more capable of fitting its central 1-(4-nitrobenzyl)-
1,2,3-triazole side-chain within the TCR CDR3 loops. Even 
though the observed T-cell responses are about one-third to 
one-half lower than those triggered by the native EAA antigenic 
peptide in terms of IFNγ and CD107a secretion, these results 
constitute an additional and sound experimental demonstration 
of the possibility of replacing natural amino acid side-chains of 
antigenic peptides with non-peptidic motifs still capable of 
eliciting T-cell responses. 
Conclusions 
A computer-aided design of peptidomimetics was based on the 
replacement of the central amino acid residues of the Melan-
A/MART-1 ELA antigenic peptide by a clickable hapten-
presenting platform. This approach enabled the generation of 
short series of ELA-mimetics equipped with a 1,4-disubstituted 
1,2,3-triazole motif bearing variously substituted aromatic 
moieties. Even though none of our first eleven ELA-mimetics 
could reach the level of binding affinity to the MHC-I HLA-A2 
molecule observed for the ELA peptide, the p-nitrobenzyl-
bearing ELA-mimetic 11 was found to elicit Melan-A-specific T-
cell responses. Further modifications of its N- and C-extremities 
aimed at restoring a higher level of HLA-A2 binding affinity led to 
seven additional ELA-mimetics. All seven compounds were 
expectedly observed to be much better HLA-A2 binders than 11, 
but it is the weakest ligand 20 of this series, simply featuring a 
reduced leucine-to-threonine amide bond, that triggers the most 
significantly enhanced T-cell stimulation. Thus, this work (i) 
further demonstrates that the affinity of an antigenic peptide (or 
mimetics thereof) to MHC-I molecules does not necessarily 
correlate with immunogenicity, and (ii) clearly highlights the 
flexibility of TCRs to cross-react with synthetic MHC-I bound 










































structurally little in common with native central amino acids. A 
recent study demonstrated that a non-biologic T-cell ligand could 
protect humanized (HLA-A2+) mice against a lethal challenge 
with influenza virus.[30] This D-peptide had almost no sequence 
similarity to the wildtype L-peptide sequence and was effective 
even though HLA-A2 binding was far weaker than that of our 
agonistic ELA-mimetics.[30] A further study has shown that an 
altered peptide ligand could induce an improved response to the 
HLA-A2-restricted EAAGIGILTV epitope studied here.[31] In 
combination, these new developments suggest that it might be 
possible to build non-biologic, biostable ligands that induce 
improved Melan-A/MART-1 specific T-cell responses. Our study 
here demonstrates that the design of peptidomimetic MHC-I 
ligands remains a valid option for the elaboration and 
development of synthetic antigens as immunotherapeutic agents. 
Experimental Section 
Docking Methodology. All molecular modeling calculations were 
performed on a Silicon Graphics Octane workstation using Cerius2 4.7 
molecular modeling softwares. First, the three-dimensional structure of 
the A6-TCR/Tax5K-IBA/HLA-A2 complex was taken from the PDB file 
2GJ6. The Tax5K-IBA peptide ligand and all water molecules were 
removed. Hydrogen atoms were added using the Cerius2 templates for 
the protein residues. The 18 ELA-mimetic structures were constructed 
using Catalyst. Partial charges were assigned using the Gasteiger 
method[32] as implemented in Cerius2. A site model based on the Tax5K-
IBA ligand, docked within the protein complex, was identified by 
LigandFit. Then, the docking[33] of the 18 ELA-mimetic ligands employed 
the following protocol: (a) a Monte Carlo conformational search for 
generating a candidate ligand conformation, (b) selection of a ligand 
position and orientation based on comparing the shape of the binding site 
model with that of the ligand conformation, and (c) evaluation of the 
goodness of docking by computing the dock energies using a grid-based 
energy calculation. The dock energy was expressed as the sum of the 
ligand internal strain energy and the interaction energy of the ligand with 
the protein. The position and the orientation of the ligand were optimized 
by minimizing the dock energy in respect to rigid body translations and 
rotations of the ligand using a steepest descent method. The docked 
conformations found were then clustered, and the first 20 were saved. A 
superimposition of the highest docked structure (the lowest in terms of 
energy) was obtained for each peptidomimetic with plausible 
consequence of their higher structural diversity. The parental peptide 
structure from the 2GJ6 PDB file enabled us to gain insight into the 
consequences of backbone modifications on the interactions with the 
protein complex. 
Material and Methods. All reagents were either purchased from Aldrich, 
Acros, or Fluka. Amino acids, Wang resin, and N,N,N’,N’-tetramethyl-O-
(1H-benzotriazol-1-yl)uronium hexafluorophosphate (HBTU) were 
purchased from Novabiochem (Switzerland). All solution phase reactions 
were carried out under nitrogen (N2) atmosphere with magnetic stirring. 
Tetrahydrofuran (THF), diethyl ether (Et2O) and dichloromethane 
(CH2Cl2) were dried through alumina columns. All other organic solvents 
were of analytical quality and Milli-Q (Millipore) water was used for 
reverse phase (RP) HPLC analyses and purifications. Peptide and 
peptidomimetic syntheses were performed manually in a glass reactor 
(vide infra). RP-HPLC analyses were performed on a Thermo system 
using a Chromolith performance RP-18e column (4.6 × 100 mm, 5 µm) 
with P1000 XR pumps. The mobile phase was composed of 0.1% (v/v) 
TFA-H2O (Solvent A) and 0.1% TFA-CH3CN (Solvent B). A gradient 
elution (0-10 min: 100% to 50% A) was applied at a flow rate of 3 
mL.min-1. Column effluent was monitored by UV detection at 214 and 254 
nm using a Thermo UV 6000 LP diode array detector. Semi-preparative 
purification of peptides were performed on a Varian PrepStar system with 
SD-1 Dynamax® pumps, using a Microsorb C18 column (2.14 mm ´ 250 
mm, 100 Å pore size, 5 µm). The mobile phase was similar as for the 
analytic system, unless otherwise notified. A gradient elution (0-40 min: 
90% to 50% A) was applied at a flow rate of 20 mL.min-1. Column effluent 
was monitored by UV detection at 214 and 254 nm using a Varian UV-
Vis Prostar 325 diode array detector. Flash column chromatography was 
carried out under positive pressure using 40-60 µm silica gel (Merck) and 
the indicated solvents. Evaporations were conducted under reduced 
pressure at temperatures less than 40 °C. Further drying of the residues 
was accomplished under high vacuum. NMR spectra of organic 
molecules were recorded at 300 MHz on a Bruker DPX spectrometer in 
the appropriated solvent. Electrospray ionization mass spectrometric low- 
and high-resolution data (ESIMS, HRMS) were obtained from the Mass 
Spectrometry Laboratory at the European Institute of Chemistry and 
Biology (IECB), Pessac, France. 
Peptidomimetic Synthesis. Peptidomimetics were synthesized by 
manual solid phase peptide synthesis (SPPS) using Fmoc chemistry on 
Wang resin (0.65 mmol.g–1) following standard SPPS protocols. Briefly, 
to a solution of N-Fmoc-Val-OH (10 equiv. relative to resin loading) in dry 
CH2Cl2 (a few drops of DMF were required to ensure complete 
dissolution) under N2 was added diisopropylcarbodiimide (DIC, 5 equiv.). 
The reaction mixture was stirred for 20 min at 0°C. In the meantime, the 
resin was suspended in dry CH2Cl2 and allowed to swell for 20 min. After 
filtration, the N-Fmoc-Val symmetrical anhydride solution and 4-
dimethylaminopyridine (DMAP, 0.1 equiv. relative to the anhydride) were 
added, and the resin was shaken for 4 h. After filtration, the resin was 
successively washed twice with DMF, CH3OH, CH2Cl2 and again DMF. 
The Fmoc protecting group was removed by using twice a solution of 
piperidine in DMF (1:4, v/v) for 3 min, then for 7 min. After filtration, the 
resin was successively washed as before. The SPPS was continued 
using N-Fmoc amino acids (3 equiv.) in the presence of HBTU (3 equiv.) 
and DIPEA (5 equiv.) in DMF. Each coupling reaction was performed for 
45 min, after which time the resin was washed as before.  
Preparation of Resin 5. To the H-AMBA-LTV peptoid construct on Wang 
resin (1 g, 0.45 mmol) pre-swelled in DMF (5 mL) was added a 0.4 M 
solution of bromoacetic acid (438 mg, 3.15 mmol) in DMF and a 2 M 
solution of DIC (562 µL, 3.60 mmol) in DMF (see Scheme 2). After 5 min, 
the resin was filtrated and washed as described above. Then, a 1 M 
solution of propargylamine (309 µL, 4.50 mmol) in DMSO was added to 
the resin and the reaction was stirred for 1 h. After washing of the resin 
and confirmation of the presence of a secondary amine via the chloranil 
test, the resin was swollen in a solution of 1% acetic acid (AcOH) in DMF, 
then Fmoc-Gly-H (567 mg, 2.7 mmol) followed by NaBH3CN (424 mg, 
6.75 mmol) were added. After 5 h, the resin was filtered off and 
successively washed with CH3OH, DMF, CH2Cl2 and again DMF. After 
removal of the Fmoc-protecting group, the other amino acids were 
coupled by following standard SPPS protocols as briefly described above 
to furnish the resin 5 (see Scheme 2).  
Preparation of Resins 6 by Click Conjugation. To a suspension of resin 5 
in a dry THF-DMF mixture (1:1) was added copper iodide (CuI, 1 mg, 5% 
M), a solution of each azides R–N3 (10 equiv., see Scheme 2) in dry 
THF-DMF (1:1) and DIPEA (5 equiv.). After stirring overnight, the resins 
were washed twice with DMF and CH2Cl2. 
Release of ELA-mimetics 7-18 from Resin. Final deprotection and 
cleavage from the resins were carried out using a TFA-H2O-
triisopropylsilane (TIS) mixture (95:2.5:2.5, v/v/v) for 4 h. The 
peptidomimetics were precipitated using cold Et2O and then filtered. The 
filtrates were washed with cold Et2O, and the peptidomimetics were 
extracted from the residues with H2O-CH3CN mixtures containing 0.1% 
TFA. The resulted solutions were frozen and lyophilized to afford the 
ELA-mimetics 7-18 as white solids. These crude products were checked 




Preparation of Resin-Bound ELA-mimetics 20-22 and 24. To the H-TV 
dipeptide construct on Wang resin (270 mg, 0.13 mmol) pre-swelled in a 
solution of 1% AcOH in DMF was added Fmoc-Leu-H[34] (0.40 mmol) and 
NaBH3CN (59 mg, 0.94 mmol). The resin was shaken for 2 h after which 
time it was filtered off and successively washed with MeOH, DMF, 
CH2Cl2 and again DMF. Coupling with the AMBA residue was then 
performed, and the preparation of these resin-bound ELA-mimetics was 
continued according to the general procedures described for the 
preparation of resins 5 and 6. 
Incorporation of the Phthalimide Moiety on Resin-Bound ELA-mimetics 
19 and 22-24.[35] To the corresponding resin-bound peptidomimetic 
intermediates without the terminal b-Ala residue and suspended in DMF 
was added phthalimide anhydride (5 equiv.) and DIPEA (5 equiv.). After 
1 h, each resulting resin was filtered off and washed according to our 
standard procedure (vide infra). Each resin was again swollen in DMF, 
and HBTU (1.5 equiv.), hydroxybenzotriazole (HOBt, 1.5 equiv.) and 
DIPEA (3 equiv.) were successively added. After stirring overnight, the 
resins were filtered off and washed according to our standard procedure. 
The release from resin and final deprotection of ELA-mimetics 19-24 
were carried out as described for the ELA-mimetics 7-18 (vide infra). 
Peptidomimetic-MHC binding assay. The mutant LCL T-
lymphoblastoid hybrid cell line, 174xCEM.T2 (referred to as T2 cells) is 
an antigen-presenting mutant line. The cells express stable HLA-A2 
molecules on their surface upon addition of an exogenous HLA-A2-
binding peptide. T2 cells were incubated with the ELA-mimetics 7-24 at 
10 µM in AIM-V serum-free medium (Invitrogen Co., Carlsbad, California) 
at 26 °C for 16 h, followed by incubation at 37 °C for 2 h. Quantification of 
stable surface HLA was analyzed by surface staining using the anti-HLA-
A2-FITC BB7.2 antibody (from the ATCC hybridoma HB-82), and 
measured as mean fluorescent intensity (MFI) on a FACSCanto II flow 
cytometer (BD Biosciences). 
T-cell Stimulation. 2x106 HLA-A2+ PBMC were cultured for 3 days in in 
the presence of 10 µM of the native EAA peptide in RPMI media in a 24-
well plate. At day 3, the culture was supplemented with T-cell media 
(10% human serum in RPM, R10). At day 10, the T-cell culture resulted 
in approximately 15% of the total CD8+ population measured by Melan-
A-HLA-A2 APC tetramer by flow cytometry. For intracellular staining, T 
cells were rested overnight at 1x106 per mL in R2 (as for R10 with 2% 
FCS) and added to peptide-pulsed targets (i.e., HLA A*0201+-C1R 
pulsed with 10 μM of the native EAA peptide or our ELA-mimetics) at an 
effector:target ratio of 1:2 (i.e., T-cell culture effectors:HLA A*0201+-C1R 
targets) in the presence of 5 µg/mL brefeldin A (Sigma-Aldrich), 0.35 
μl/mL monensin and 5 µl/mL aCD107a-FITC (BD Biosciences). After 5 h 
at 37 °C, the cells were washed and stained with LIVE/DEAD Fixable 
Aqua (Life Technologies) followed by anti-CD3-PacificBlue, anti-CD8-
APCH7 (BioLegend). The cells were then fixed/permeabilized using a 
Cytofix/Cytoperm Kit (BD Biosciences) and stained intracellularly with 
anti-IFNγ-PECy7 on ice for 30 min. Data were acquired using a 
FACSCanto II flow cytometer (BD Biosciences) and analyzed with 
FlowJo software (Tree Star Inc.). Cell population gates were set using 
fluorescence minus one staining control. ICS MFIs are shown. 
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Click to fit. A computer-aided construction of a short series of mimetics of the tumor-derived Melan-A/MART-126(27L)-35 antigenic 
peptide ELAGIGILTV was achieved by clicking aromatic azido haptens on a propargylated GIGI-mimicking central platform. Out of a 
total of only 18 peptidomimetcis thus synthesized, one of the most heavily modified constructs harboring a p-nitrobenzyl moiety 
elicited significant Melan-A-specific T-cell responses.  
